AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31415451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 20
Study 31415451 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 30342638 — intervention group
Group type: EXPERIMENTAL
Intervention: Family medicine clerkships
Number of subjects: 738
Study 30342638 — intervention group
Group type: COMPARATOR
Intervention: Obstetrics and gynecology clerkships
Number of subjects: 738
Study 30342638 — intervention group
Group type: COMPARATOR
Intervention: Internal medicine clerkships
Number of subjects: 738
Study 28636754 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 360
Study 28636754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 26204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (2-310 mg)
Number of subjects: 575
Study 26204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl (75-125 mg)
Number of subjects: 575
Study 26204387 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 575
Study 26204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Number of subjects: 575
Study 26204387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Number of subjects: 575
Study 24252583 — intervention group
Group type: EXPERIMENTAL
Intervention: RE leading to failure (3 sets of 10 repetitions maximum)
Number of subjects: 10
Study 24252583 — intervention group
Group type: EXPERIMENTAL
Intervention: RE not to failure (60% of 10-RM, 3 sets of 10 repetitions)
Number of subjects: 10
Study 24252583 — intervention group
Group type: COMPARATOR
Intervention: Control (40 minutes of seated rest)
Number of subjects: 10
Study 24252583 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of 10-RM and 10-RM sessions
Number of subjects: 10
Study 20595155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (160 μg s.i.d.)
Number of subjects: 37
Study 20595155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (100 μg b.i.d.)
Number of subjects: 37
Study 18291270 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit root canal therapy
Number of subjects: 97
Study 18291270 — intervention group
Group type: COMPARATOR
Intervention: Two-visit root canal therapy with calcium hydroxide/chlorhexidine paste dressing
Number of subjects: 97
Study 16603430 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal preparation
Number of subjects: 97
Study 12959906 — intervention group
Group type: EXPERIMENTAL
Intervention: Active collision production
Number of subjects: 0
Study 12959906 — intervention group
Group type: COMPARATOR
Intervention: Imposed collision
Number of subjects: 0
Study 12959906 — intervention group
Group type: COMPARATOR
Intervention: Imposed collision with visual feedback
Number of subjects: 0
Study 10722988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics that implemented a preventive services delivery system
Number of subjects: 22
Study 10722988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics that did not implement a preventive services delivery system
Number of subjects: 22
Study 10722988 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROVE project and managed care organizations' efforts
Number of subjects: 22
Study 10722988 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study 8958016 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound (CDUS) and power flow imaging
Number of subjects: 47
Study 8958016 — intervention group
Group type: COMPARATOR
Intervention: Control group (benign and malignant adrenal masses)
Number of subjects: 47
Study 29613944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10-Hz stimulation, 20 daily treatments)
Number of subjects: 84
Study 29613944 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 84
Study 29613944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 84
Study 29613944 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quality of episodic memory
Number of subjects: 84
Study 29284438 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPaCT Therapy
Number of subjects: 406
Study 29284438 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPaCT Therapy (>180 min)
Number of subjects: 406
Study 29284438 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 406
Study 26268913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry (500 mg daily for 6 months)
Number of subjects: 182
Study 26268913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 26268913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry
Number of subjects: 182
Study 23384111 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel applied to half of the chest scar for three months
Number of subjects: 20
Study 23384111 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of the chest scar)
Number of subjects: 20
Study 21237406 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation group
Number of subjects: 100
Study 21237406 — intervention group
Group type: COMPARATOR
Intervention: Mobilization group
Number of subjects: 100
Study 21237406 — intervention group
Group type: COMPARATOR
Intervention: No-pop group
Number of subjects: 100
Study 21237406 — intervention group
Group type: COMPARATOR
Intervention: Multiple-pop group
Number of subjects: 100
Study 18327093 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg and Delapril 30 mg
Number of subjects: 314
Study 18327093 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg and Hydrochlorothiazide 12.5 mg
Number of subjects: 314
Study 15996001 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO(2) concentration in plasma from patients with MAT I/III deficiency
Number of subjects: 4
Study 15996001 — intervention group
Group type: COMPARATOR
Intervention: DMSO(2) concentration in cerebrospinal fluid (CSF) and plasma
Number of subjects: 4
Study 12239448 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise hook extension technique for radiofrequency ablation (RFA)
Number of subjects: 20
Study 12239448 — intervention group
Group type: COMPARATOR
Intervention: Full extension method for radiofrequency ablation (RFA)
Number of subjects: 20
Study 10321152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 33
Study 10321152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8938004 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory line motion with an interstimulus interval (ISI) of a few hundred milliseconds
Number of subjects: 0
Study 8938004 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast polarity manipulation (dots brighter than background vs. dots darker and lines brighter)
Number of subjects: 0
Study 8938004 — intervention group
Group type: EXPERIMENTAL
Intervention: Display size manipulation (two, four, or eight pairs of dots and lines)
Number of subjects: 0
Study 1890269 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐methoxypsoralen (8‐MP) at a dose of 10 mg followed by UVA irradiation (1 joule/cm2)
Number of subjects: 0
Study 1890269 — intervention group
Group type: COMPARATOR
Intervention: UVA irradiation alone
Number of subjects: 0
Study 1890269 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐MP plus UVA irradiation (increasing doses from 10 to 30 mg)
Number of subjects: 0
Study 6754210 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 6754210 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 6754210 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose Methyldopa
Number of subjects: 0
Study 6754210 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose Propranolol
Number of subjects: 0
Study 31308497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange-only qubit encoded in a subsystem of three coupled electron spins
Number of subjects: 0
Study 27859337 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 20942
Study 27859337 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 20942
Study 27859337 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 20942
Study 27195511 — intervention group
Group type: EXPERIMENTAL
Intervention: ET (exercise training)
Number of subjects: 15
Study 27195511 — intervention group
Group type: EXPERIMENTAL
Intervention: ET+IL (exercise training with inspiratory load)
Number of subjects: 15
Study 23668847 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrastructure for walking
Number of subjects: 434
Study 23668847 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to services
Number of subjects: 434
Study 23668847 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 434
Study 23668847 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported walking
Number of subjects: 434
Study 23168147 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove finger-coated polyvinyl acetate pack
Number of subjects: 30
Study 23168147 — intervention group
Group type: COMPARATOR
Intervention: PA pack (Merocel; Medtronic Xomed)
Number of subjects: 30
Study 19384691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of sorafenib and erlotinib
Number of subjects: 0
Study 19384691 — intervention group
Group type: COMPARATOR
Intervention: Control group (active standard treatment)
Number of subjects: 0
Study 18075941 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental supported employment program
Number of subjects: 1273
Study 18075941 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1273
Study 15234027 — intervention group
Group type: COMPARATOR
Intervention: Once-daily radiotherapy (q.d. RT) - 50.4 Gy in 28 fractions
Number of subjects: 261
Study 15234027 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily radiotherapy (b.i.d. RT) - 24 Gy in 16 fractions, a 2.5-week break, and 24 Gy in 16 fractions
Number of subjects: 261
Study 11907636 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg/d)
Number of subjects: 95
Study 11907636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 11907636 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/d)
Number of subjects: 95
Study 9270900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (75, 150, 300, 600, or 750 mg daily)
Number of subjects: 361
Study 9270900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (300 mg daily)
Number of subjects: 361
Study 9270900 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (12 mg daily)
Number of subjects: 361
Study 9270900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 9270900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (all doses)
Number of subjects: 361
Study 7894807 — intervention group
Group type: EXPERIMENTAL
Intervention: Granuflex Extra Thin
Number of subjects: 96
Study 7894807 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing (perforated film absorbent dressing)
Number of subjects: 96
Study 3365008 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya based substitute
Number of subjects: 487
Study 3365008 — intervention group
Group type: COMPARATOR
Intervention: Cows' milk preparations
Number of subjects: 487
Study 3365008 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 487
Study 31448802 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam roller maneuver (group 2)
Number of subjects: 40
Study 31448802 — intervention group
Group type: COMPARATOR
Intervention: No steam roller maneuver (group 1)
Number of subjects: 40
Study 28585932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention
Number of subjects: 81
Study 28585932 — intervention group
Group type: COMPARATOR
Intervention: Education-based placebo intervention
Number of subjects: 81
Study 25266695 — intervention group
Group type: EXPERIMENTAL
Intervention: PAG training (n=12)
Number of subjects: 23
Study 25266695 — intervention group
Group type: COMPARATOR
Intervention: Active control (CON, n=11)
Number of subjects: 23
Study 23425819 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin 1.5g every 8 hrs for up to 28 days
Number of subjects: 194
Study 23425819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 23425819 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin
Number of subjects: 194
Study 21190079 — intervention group
Group type: EXPERIMENTAL
Intervention: Central HER2 evaluation
Number of subjects: 278
Study 21190079 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 mRNA expression
Number of subjects: 278
Study 21190079 — intervention group
Group type: COMPARATOR
Intervention: Local HER2 evaluation
Number of subjects: 278
Study 18032739 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 808
Study 18032739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 18032739 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (wake-up cohort)
Number of subjects: 808
Study 17068892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 59
Study 17068892 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 59
Study 12607650 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose: 3 x 10(4) KIU/kg plus a bolus of 5 x 10(5) KIU)
Number of subjects: 60
Study 12607650 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 60
Study 8723579 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg
Number of subjects: 103
Study 8723579 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 600 IU/kg
Number of subjects: 103
Study 8723579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 1649575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (up to 3,200 mg/day)
Number of subjects: 104
Study 1649575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 1649575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 104
Study 6631803 — intervention group
Group type: EXPERIMENTAL
Intervention: manual aural toilet followed by aural drops
Number of subjects: 26
Study 6631803 — intervention group
Group type: COMPARATOR
Intervention: drops only
Number of subjects: 26
Study 30866967 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Training
Number of subjects: 10
Study 30866967 — intervention group
Group type: EXPERIMENTAL
Intervention: Core + Facilitation
Number of subjects: 10
Study 30145671 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-alloy suprapubic catheter
Number of subjects: 288
Study 30145671 — intervention group
Group type: COMPARATOR
Intervention: Standard suprapubic catheter
Number of subjects: 288
Study 27959709 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal-flow pump
Number of subjects: 294
Study 27959709 — intervention group
Group type: COMPARATOR
Intervention: Axial-flow pump
Number of subjects: 294
Study 26210096 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Navigation System (LNS)
Number of subjects: 58
Study 26210096 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 58
Study 23241003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg twice a day for 2 weeks, then 50 mg 3 times a week for 10 weeks
Number of subjects: 106
Study 23241003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 106
Study 23241003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 21909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri‐Oss rubber matrices
Number of subjects: 106
Study 21909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Branemark gold matrices
Number of subjects: 106
Study 21909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern plastic matrices
Number of subjects: 106
Study 21909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Straumann gold matrices
Number of subjects: 106
Study 21909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern gold/platinum, Branemark gold, Southern plastic matrices
Number of subjects: 106
Study 21909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures
Number of subjects: 106
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677TT genotype
Number of subjects: 659
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR T allele
Number of subjects: 659
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: MTR 2756GG genotype
Number of subjects: 659
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: DNMT3b C‐‐>T (rs406193) polymorphism
Number of subjects: 659
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMT2 G‐‐>A (rs535586) polymorphism
Number of subjects: 659
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: MTR A2756G
Number of subjects: 659
Study 19843671 — intervention group
Group type: EXPERIMENTAL
Intervention: MTRR A66G
Number of subjects: 659
Study 16905695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation (MPEC)
Number of subjects: 35
Study 16905695 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 35
Study 15659891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of ketorolac
Number of subjects: 42
Study 15659891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of oxybutynin
Number of subjects: 42
Study 15659891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of alkalinized lidocaine
Number of subjects: 42
Study 15659891 — intervention group
Group type: COMPARATOR
Intervention: Control solution (0.9% sodium chloride)
Number of subjects: 42
Study 11534420 — intervention group
Group type: COMPARATOR
Intervention: OCA‐7 (omeprazole 20 mg b.i.d., amoxycillin 1 gr b.i.d., clarithromycin 500 mg b.i.d.)
Number of subjects: 200
Study 11534420 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCA (ranitidine bismuth citrate 400 mg b.i.d., amoxicillin 1 gr b.i.d., clarithromycin 500 mg b.i.d.)
Number of subjects: 200
Study 9574474 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (Group 2, n = 74)
Number of subjects: 220
Study 9574474 — intervention group
Group type: COMPARATOR
Intervention: No spa therapy (Group 3, n = 74)
Number of subjects: 220
Study 9574474 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (Group 1, n = 72)
Number of subjects: 220
Study 8160893 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly labeled water (DLW) method
Number of subjects: 6
Study 8160893 — intervention group
Group type: COMPARATOR
Intervention: Intake balance (I‐B) method
Number of subjects: 6
Study 8160893 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of DLW and I‐B methods
Number of subjects: 6
Study 3342283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablets (T)
Number of subjects: 8
Study 3342283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release microgranules (MG)
Number of subjects: 8
Study 3342283 — intervention group
Group type: COMPARATOR
Intervention: High-protein test meal with T
Number of subjects: 8
Study 31893475 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles published in the journal
Number of subjects: 132
Study 29273732 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) counseling session (90 minutes)
Number of subjects: 80
Study 29273732 — intervention group
Group type: COMPARATOR
Intervention: Routine procedures (Control)
Number of subjects: 80
Study 26264474 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT (tension-free vaginal tape)
Number of subjects: 140
Study 26264474 — intervention group
Group type: COMPARATOR
Intervention: TVT-O (inside-out transobturator tape)
Number of subjects: 140
Study 26264474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 140
Study 26016859 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg magnesium oxide
Number of subjects: 70
Study 26016859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22456691 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (12-week dietary weight-loss programme)
Number of subjects: 49
Study 21999623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg bolus prior to surgery)
Number of subjects: 66
Study 21999623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin spray (10 mL during surgery)
Number of subjects: 66
Study 21999623 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither treatment)
Number of subjects: 66
Study 18782316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment (MU)
Number of subjects: 134
Study 18782316 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (SU)
Number of subjects: 134
Study 16928979 — intervention group
Group type: EXPERIMENTAL
Intervention: FRISK score based on multiple-site BMD measurements and risk factors
Number of subjects: 679
Study 16928979 — intervention group
Group type: COMPARATOR
Intervention: FRISK score
Number of subjects: 679
Study 14711063 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss strategies
Number of subjects: 0
Study 14711063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention trials
Number of subjects: 0
Study 10844933 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal lesions (neoplastic lesions in the distal colon)
Number of subjects: 3268
Study 10844933 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal lesions (neoplastic lesions in the proximal colon)
Number of subjects: 3268
Study 10844933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both distal and proximal lesions
Number of subjects: 3268
Study 10844933 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous proximal lesions
Number of subjects: 3268
Study 10844933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadvanced lesion in the distal colon
Number of subjects: 3268
Study 10844933 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced lesion in the distal colon
Number of subjects: 3268